

**Abingdon Health plc**  
("Abingdon Health" or "the Company")

**Senzo and Abingdon Health enter into strategic partnership**

*Abingdon Health's CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities*

Senzo Health Limited (London, UK) ("Senzo") and Abingdon Health plc (York, UK) ("Abingdon Health") announce the signing of a strategic partnership agreement.

Under the terms of the partnership Abingdon Health will support Senzo by providing contract development and manufacturing ("CDMO") services to Senzo and its partners to enable them to develop and manufacture new rapid tests utilising Senzo's cutting-edge ALF platform.

Senzo is a leading innovator in the rapid diagnostics testing market, with its revolutionary lateral flow technology delivering the same accuracy as laboratory-based PCR with results available within 10 minutes, at a fraction of the cost. Senzo Health's technology is initially being applied to the development of a Covid-19 antigen assay, a broader respiratory panel, and other infectious disease tests. However, there are a wide range of applications across clinical, animal health, food, plant pathogen and environmental testing that would benefit from strengths of Senzo's platform technology. This strategic partnership will allow Senzo's partners to accelerate product development through access to Abingdon Health's CDMO services.

Abingdon Health is a leading lateral flow CDMO offering its services to an international customer base across a range of industry sectors. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success". All projects are managed through Abingdon Health's quality management system and its services include feasibility, optimisation, technical transfer, manufacturing, regulatory and commercial support. Its UK-based automated manufacturing operations are capable of producing tens of millions of lateral flow tests per annum.

**Jeremy Stackawitz, CEO of Senzo Health, commented:** *"This new partnership, with such an established, innovative, and trusted group as Abingdon, is a terrific opportunity for Senzo as we seek to expand the tests being developed and brought to market on our game-changing ALF platform. Collaborating with Abingdon creates a valuable synergy for customers looking to bring innovative, high-performance lateral flow products to market, and we're extremely eager to get to work on the first assays."*

**Chris Yates, CEO of Abingdon Health, commented:** *"We are really excited to be working with Senzo and supporting them in leveraging their cutting-edge lateral flow platform technology across multiple applications. We believe this strategic partnership agreement provides Senzo Health and its customers with access to Abingdon's best-in-class CDMO service to enable accelerated product development and time to market."*

**Enquiries**

**Abingdon Health plc**

Chris Yates, Chief Executive Officer  
Melanie Ross, Chief Financial Officer

[www.abingdonhealth.com/investors/](http://www.abingdonhealth.com/investors/)  
Via Walbrook PR

**Walbrook PR Limited**

Paul McManus / Phillip Marriage  
Alice Woodings

Tel: +44 (0)20 7933 8780 or [abingdon@walbrookpr.com](mailto:abingdon@walbrookpr.com)  
Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082  
+44 (0)7407 804 654

**About Senzo:**

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies, with a focus on enhanced sensitivity, to create mobile, point-of-care and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products and systems which bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. [www.senzo.com](http://www.senzo.com)

**About Abingdon Health plc:**

Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes.

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The [Abingdon Simply Test](#) ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site

provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: [www.abingdonhealth.com](http://www.abingdonhealth.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAGPUQAWUPWGQM